线性免疫印迹法检测慢性炎性脱髓鞘性多神经病患者的抗神经节苷脂抗体
该研究采用多重半定量线性免疫印迹法(LIA)检测61例炎性神经病(IN)患者(含27例典型CIDP)、40例其他神经肌肉疾病(OND)、29例多发性硬化(MS)和54例健康对照(HC)的11种神经节苷脂及硫酸脂(SF)抗体。结果显示IN组至少一种抗神经节苷脂/SF IgM阳性率27.9%,显著高于OND组5%、MS组6.9%和HC组7.4%(p=0.001);抗SF IgM在IN组较OND组更高(p=0.008),抗GM1 IgM在IN组较OND和HC组更高(p=0.009),抗GD1b在IN组较HC组更高(p<0.04)。CIDP组抗GM1 IgM阳性率低于多灶性运动神经病(MMN)组(12% vs. 60%,p=0.027)。抗SF、抗GM1和抗GM2 IgM阳性患者较抗体阴性者年轻(p<0.05),抗SF IgM阳性者更常见典型CIDP和MMN表型(p<0.05)。
要点
- IN组至少一种抗神经节苷脂/SF IgM阳性率27.9%,显著高于OND、MS和HC组。
- 抗SF IgM在IN组较OND组更常见(p=0.008),抗GM1 IgM在IN组较OND和HC组更常见(p=0.009)。
- CIDP组抗GM1 IgM阳性率低于MMN组(12% vs. 60%,p=0.027)。
核心结论
- LIA检测显示CIDP/MMN患者至少一种抗神经节苷脂抗体IgM阳性频率升高,抗SF、抗GM1和抗GM2 IgM与较年轻年龄相关,抗SF与IN表型相关。
研究设计与样本
- 研究采用多重半定量线性免疫印迹法检测61例IN患者(27例典型CIDP、12例远端获得性脱髓鞘性多神经病、6例多灶性获得性脱髓鞘感觉/运动多神经病、10例感觉型CIDP、1例局灶性CIDP和5例多灶性运动神经病)、40例OND(15例非免疫性多神经病、25例重症肌无力)、29例MS和54例HC的11种神经节苷脂及硫酸脂抗体。
主要发现
- IN组至少一种抗神经节苷脂/SF IgM阳性率为17/61(27.9%),OND组为2/40(5%),MS组为2/29(6.9%),HC组为4/54(7.4%),组间比较p=0.001。
- 抗SF IgM在IN组较OND组更常见(p=0.008);抗GM1 IgM在IN组较OND和HC组更常见(p=0.009);抗GD1b在IN组较HC组更常见(p<0.04)。
- CIDP组抗GM1 IgM阳性率低于MMN组(12% vs. 60%,p=0.027)。
- 抗SF、抗GM1和抗GM2 IgM阳性患者较抗体阴性者年轻(p<0.05)。
- 抗SF IgM阳性患者更常见典型CIDP和MMN表型(p<0.05)。
临床怎么用
- 对于CIDP/MMN患者,LIA检测抗神经节苷脂抗体IgM(尤其抗SF、抗GM1)可能有助于免疫介导神经病的鉴别诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unlike for acute immune-mediated neuropathies (IN), anti-ganglioside autoantibody (aGAAb) testing has been recommended for only a minority of chronic IN yet. Thus, we used a multiplex semi-quantitative line immunoassay (LIA) to search for aGAAb in chronic-inflammatory demyelinating polyneuropathy (CIDP) and its clinical variants. METHODS: Anti-GAAb to 11 gangliosides and sulfatide (SF) were investigated by LIA in 61 patients with IN (27 typical CIDP, 12 distal-acquired demyelinating polyneuropathy, 6 multifocal-acquired demyelinating sensory/motor polyneuropathy, 10 sensory CIDP, 1 focal CIDP and 5 multifocal-motoric neuropathy), 40 with other neuromuscular disorders (OND) (15 non-immune polyneuropathies, 25 myasthenia gravis), 29 with multiple sclerosis (MS) and 54 healthy controls (HC). RESULTS: In contrast to IgG, positive anti-GAAB IgM against at least one ganglioside/SF was found in 17/61 (27.9%) IN compared to 2/40 (5%) in OND, 2/29 MS (6.9%) and 4/54 (7.4%) in HC (p=0.001). There was a statistically higher prevalence of anti-sulfatide (aSF) IgM in IN compared to OND (p=0.008). Further, aGM1 IgM was more prevalent in IN compared to OND and HC (p=0.009) as well as GD1b in IN compared to HC (p<0.04). The prevalence of aGM1 IgM in CIDP was lower compared to in multifocal motor neuropathy (MMN) (12% vs. 60%, p=0.027). Patients showing aSF, aGM1 and aGM2 IgM were younger compared to aGAAb negatives (p<0.05). Patients with aSF IgM positivity presented more frequently typical CIDP and MMN phenotypes (p<0.05, respectively). CONCLUSIONS: The aGAAb LIA revealed an elevated frequency of at least one aGAAb IgM in CIDP/MMN patients. Anti-SF, aGM1 and aGM2 IgM were associated with younger age and anti-SF with IN phenotypes.
引用
- Klehmet J, Märschenz S, Ruprecht K, et al. Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab Med. 2018. PMID: 29329103. doi:10.1515/cclm-2017-0792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。